Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on October 22, 2015, to report financial results for the quarter ended September 30, 2015. The filing includes unaudited condensed consolidated financial statements and an updated discussion of risk factors.
Key Financial Metrics
- Revenue: $13.9 million for Q3 2015, comprised of $10.3 million in product/service revenue and $3.6 million in contractual revenue.
- Gross Profit: $6.6 million, representing a gross margin of 47.1%.
- Operating Expenses: Reported as $3.9 million net, reflecting $26.9 million in aggregate expenses offset by a one-time gain on lease amendments of $23.0 million.
- Net Income: $1.8 million, or $0.02 per share (basic and diluted).
- Liquidity: Cash and investments totaled $58.9 million as of September 30, 2015.
Material Changes Versus Prior Period
- Revenue Decline: Revenue decreased to $13.9 million from $20.6 million in Q3 2014. This decline was driven by the absence of a $10 million milestone payment recognized in Q3 2014 under the agreement with F. Hoffman-La Roche Ltd ("Roche").
- Margin Compression: Gross margin fell to 47.1% from 63.8% in Q3 2014, primarily due to the non-recurring milestone revenue in the prior year.
- Profitability Shift: The company reported a net income of $1.8 million compared to a net loss of $9.2 million in Q3 2014. This turnaround was primarily driven by the one-time $23.0 million gain on lease amendments.
- Cash Position: Cash and investments decreased to $58.9 million from $101.3 million as of December 31, 2014.
Outlook, Risks, and Unusual Items
- Unusual Items: The Q3 2015 results were significantly impacted by a one-time gain of $23.0 million on lease amendments, which offset operating expenses and drove net income.
- Contractual Revenue: Q3 2015 contractual revenue reflected higher quarterly amortization of an upfront cash payment received in fiscal 2013 from Roche, following a revision to the estimated development period in Q1 2015.
- Forward-Looking Statements: The filing contains forward-looking statements subject to risks and uncertainties. Management notes that actual results could differ materially from anticipated results.
- Risk Factors: The company has updated its risk factors, which are incorporated by reference in Exhibit 99.4.
Investor Verification Checklist
- Verify the sustainability of the $23.0 million one-time gain on lease amendments and its impact on future operating expense projections.
- Review the terms of the Roche agreement to understand the timing and magnitude of future contractual revenue amortization versus milestone payments.
- Assess the burn rate given the significant decline in cash and investments from $101.3 million to $58.9 million over nine months.
- Examine the updated risk factors in Exhibit 99.4 for new disclosures regarding the company's financial condition or operational challenges.